a pius sign (*) more-		١ -
UTIL	IT	

PATENT APPLICATION

TRANSMITTAL

17. Priority of foreign application No.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.:

First Named Inventor: Wong, Pancras C. EL502308019US

Express Mail Label No.: Treatment of Thrombosis by Combined Use of a Factor Xa Inhibitor and Aspirin, Tissue
Plasmingen Activator (TPA), a GPIIa/IIIb Antagonist, Low Molecular Weight Heparin

TITLE: Treatment of Thrombosis by Combined 3/Hb Antagonist, Low Molecular Weight Reparts Or Heparin				
Plasmiogen Activator (2233)				
APPLICATION ELEMENTS	ADDRESS TO: Assistant Application Box Patent Application Washington, DC 20231			
Sea MPFP chapter 600 concerning utility patent application contents.	Program (Annendix)			
- I-megit account helow.)	6. Microfiche Computer Fig. and Crystal (1997) 7. Nucleotide and/or Amino Acid Sequences Submission 25 (1997) 8. Computer Readable Copy 9. Paper Copy (identical to computer copy) 9. Statement verifying identity of above copies			
3. [X] Drawing(s) (35 USC 113)[Total Pages 5] 4. [X] Oath or Declaration[Total Pages 1]	ACCOMPANYING APPLICATION PARTS 8. Power of Attorney			
a. [X] Unexecuted (original or copy)	9. Information Disclosure Statement (IDS) /Cover			
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisions with Box 14 completed)	Letter plus PTO-1449 a. Copies of IDS Citations ()			
i DELETION OF INVENTORS Signed Statement below at 15 deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 5. Incorporation by Reference (useable if Box 4b is	10. Preliminary Amendment (See item 16. below) 11. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
checked) The entire disclosure of the prior application, which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated	13. Other			
by reference therein. 14. If a CONTINUATION APPLICATION, check appropriate	box and supply the requisite information:			
Continuation G Division	Continuation Divisional			
DELETION OF INVENTOR(3) 31 A Lemon. This application is being filed by less than all the inventors named in the prior application. In accordance with 37 CFR 1.63(d)(2) and 1.33(b), the Assistant Commissioner is requested to delete the name(s) of the following person who are not inventors of the invention being claimed in this application: Amend the specification, in accordance with MPEP 201.11, by inserting before the first line the sentence:				
Amend the specification, in accordance with MPEF 2	VIII.11-7			

is claimed under 35 U.S.C. 119.

filed on

	Attorney Docket No.: PH-7038
1	First Named Inventor: Wong, Pancras C.
	First Namea Inventor: 11 2-87

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
CETTION	TOTAL CLAIMS	8 =	0	x \$ 18 =	\$0
	(37 CFR 1.16(c) INDEPENDENT	2 =	0	x \$ 78 =	\$0
	CLAIMS (37 CFR 1.16(b)			+ \$ 260 =	\$0
	DEPENDENT CLAIM(S) (if applicable)		(37	BASIC FEE CFR 1.16(a))	+ \$690.00 \$690.00
	ommissioner is hereby authors	ind to credit ov	erpayments or cha	Total = arge the following	fees to Deposit
18. The C	ommissioner is hereby auth	orized to credit o	o.p-,		

- Account No. 04-1928:
 - a. X Fees required under 37 CFR 1.16
 - b. Fees required under 37 CFR 1.17.

19. Other:

20. CORRESPONDENCE ADDRESS
20 COPPESPONDENCE ADDRESS
20. CORRESTOR
a D. Dubin
NAME: Kenneth B. Rubin
NAME: Reinfell B. Record Company 4DDRESS DuPont Pharmaceuticals Company
ADDRESS DuPont Phalmaceutical Advanced Remours and Company
c/o E. I. duront de remand
Legal - Patents
Legal - Patents
CITY Wilmington STATE Detailed (302) 992-3215 FAX (302) 992-3039
COUNTRY U.S.A. IELEFHORE

VZ	rry U.S.A.		
_		SIGNATURE OF ATTORNEY OR AGENT REQUI	₹ED
1	21		Reg. No. 36,259
	NAME	Kenneth B. Rubin	
		About 14 h dh	
	SIGNATURE	Hamet BALL	
	DATE	March 6, 2000	
	DAIL		